The Nicotinic Allosteric Potentiating Ligand Galantamine Facilitates Synaptic Transmission in the Mammalian Central Nervous System
Authors:
- Manickavasagom AlkondonMAManickavasagom Alkondon
- Edna F. R. PereiraEPEdna F. R. Pereira
- Yasco AracavaYAYasco Aracava
- Howard M. EisenbergHEHoward M. Eisenberg
- Alfred MaelickeAMAlfred Maelicke
- Edson X. AlbuquerqueEAEdson X. Albuquerque
- 1 May 2002
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 61 (5) , 1222-1234
Abstract
In this study, the patch-clamp technique was used to determine the effects of galantamine, a cholinesterase inhibitor and a nicotinic allosteric potentiating ligand (APL) used for treatment of Alzheimer9s disease, on synaptic transmission in brain slices. In rat hippocampal and human cerebral cortical slices, 1 μM galantamine, acting as a nicotinic APL, increased γ-aminobutyric acid (GABA) release triggered by 10 μM acetylcholine (ACh). Likewise, 1 μM galantamine, acting as an APL on presynaptically located nicotinic receptors (nAChRs) that are tonically active, potentiated glutamatergic or GABA-ergic transmission between Schaffer collaterals and CA1 neurons in rat hippocampal slices. The cholinesterase inhibitors rivastigmine, donepezil, and metrifonate, which are devoid of nicotinic APL action, did not affect synaptic transmission. Exogenous application of ACh indicated that high and low levels of nAChR activation in the Schaffer collaterals inhibit and facilitate, respectively, glutamate release onto CA1 neurons. The finding then that the nAChR antagonists methyllycaconitine and dihydro-β-erythroidine facilitated glutamatergic transmission between Schaffer collaterals and CA1 neurons indicated that in a single hippocampal slice, the inhibitory action of strongly, tonically activated nAChRs in some glutamatergic fibers prevails over the facilitatory action of weakly, tonically activated nAChRs in other glutamatergic fibers synapsing onto a given neuron. Galantamine is known to sensitize nAChRs to activation by low, but not high agonist concentrations. Therefore, at 1 μM, galantamine is likely to increase facilitation of synaptic transmission by weakly, tonically activated nAChRs just enough to override inhibition by strongly, tonically activated nAChRs. In conclusion, the nicotinic APL action can be an important determinant of the therapeutic effectiveness of galantamine.Keywords
This publication has 31 references indexed in Scilit:
- Tonic nicotinic modulation of serotoninergic transmission in the spinal cordProceedings of the National Academy of Sciences, 2001
- Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer’s diseaseBiological Psychiatry, 2001
- NEUROBEHAVIORAL AND NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER'S DISEASENeurologic Clinics, 2000
- Neuronal nicotinic receptors in synaptic functions in humans and rats: physiological and clinical relevanceBehavioural Brain Research, 2000
- α7 Nicotinic acetylcholine receptors and modulation of gabaergic synaptic transmission in the hippocampusEuropean Journal of Pharmacology, 2000
- Neuronal Nicotinic Receptors and Synaptic Transmission in the Mammalian Central Nervous System2000
- Nicotinic Receptor Activation in Human Cerebral Cortical Interneurons: a Mechanism for Inhibition and Disinhibition of Neuronal NetworksJournal of Neuroscience, 2000
- Choline and Selective Antagonists Identify Two Subtypes of Nicotinic Acetylcholine Receptors that Modulate GABA Release from CA1 Interneurons in Rat Hippocampal SlicesJournal of Neuroscience, 1999
- Galanthamine: pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of miceNeuropharmacology, 1991
- Alzheimer's Disease: A Disorder of Cortical Cholinergic InnervationScience, 1983